BERWYN -
Event: Virpax Presentation at the 2024
Date:
Time:
Location: Theater 3
Mr. Bruce and team members will host meetings from
About
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage severe pain, including post cancer pain. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the
Contact:
Email: Betsy.brod@affinitygrowth.com
Tel: (917) 923-8541
Email: rcavosi@rooneypartners.com
Tel: (646) 638-9891
(C) 2024 Electronic News Publishing, source